Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec;35(12):1017-1021.
doi: 10.1051/medsci/2019201. Epub 2020 Jan 6.

[Monoclonal antibodies: also for dermatologists!]

[Article in French]
Aurélie Du-Thanh  1 , Bernard Guillot  1
Affiliations
Free article
Review

[Monoclonal antibodies: also for dermatologists!]

[Article in French]
Aurélie Du-Thanh et al. Med Sci (Paris). 2019 Dec.
Free article

Abstract
in English, French

Therapeutic monoclonal antibodies are henceforth commonly used in the management of psoriasis but have been also used more recently in chronic spontaneous urticaria and atopic dermatitis. Three examples are developed herein: dupilumab, omalizumab and lanadelumab. The specificity of their mechanism of action results from a better understanding of the inflammatory pathways in these chronic diseases, which previously shared either the same targeted topical or systemic treatments. However, their high costs should be put into perspective with the epidemiology, the precise evaluation of the severity, the optimization of first line treatments and the long-term benefit/risk ratio.

Title: Anticorps monoclonaux thérapeutiques - En dermatologie aussi !

Abstract: Les anticorps monoclonaux thérapeutiques en dermatologie ont d’abord été utilisés pour la prise en charge du psoriasis, puis, plus récemment, de l’urticaire chronique spontanée et de la dermatite atopique. Trois exemples seront abordés dans cette revue: le dupilumab, l’omalizumab et le lanadélumab. Leur mode d’action spécifique résulte d’une meilleure compréhension des mécanismes inflammatoires de ces maladies chroniques qui partageaient autrefois des traitements topiques ou systémiques plus ou moins ciblés. Leur utilisation onéreuse doit cependant être raisonnée par la mise en perspective de l’épidémiologie, de l’évaluation précise de la sévérité, de l’optimisation des traitements de première ligne, et de la balance bénéfices/risques.

PubMed Disclaimer

References

    1. Jaddo. Juste après dresseuse d’ours: les histoires brutes et non romancées d’une jeune médecin généraliste. Paris: Fleuve Éditions, 2011: 304 p.
    1. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the research on adverse drug events and reports (RADAR) project. Lancet Oncol 2009 ; 10: 816–824.
    1. Richard MA, Corgibet F, Beylot-Barry M, et al. Sex- and age-adjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the « objectifs peau » study. J Eur Acad Dermatol Venereol 2018 ; 32: 1967–1971.
    1. Sandhu JK, Wu KK, Bui TL, Armstrong AW. Association between atopic dermatitis and suicidality: A systematic review and meta-analysis. JAMA Dermatol 2019 ; 155: 178–187.
    1. Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015 ; 74: 480–489.

MeSH terms

LinkOut - more resources